Biapenem | CAS#120410-24-4 | MedKoo Biosciences

MedKoo Cat#: 315145 | Name: Biapenem

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Biapenem (INN) is a carbapenem antibiotic. It has in vitro activity against anaerobes.

Chemical Structure

Biapenem

CAS#120410-24-4

Theoretical Analysis

MedKoo Cat#: 315145

Name: Biapenem

CAS#: 120410-24-4

Chemical Formula: C15H18N4O4S

Exact Mass: 350.1049

Molecular Weight: 350.39

Elemental Analysis: C, 51.42; H, 5.18; N, 15.99; O, 18.26; S, 9.15

Price and Availability

Size	Price	Availability
200mg	USD 250.00	2 Weeks
500mg	USD 450.00	2 Weeks
1g	USD 650.00	2 Weeks
2g	USD 950.00	2 Weeks
5g	USD 1,850.00	2 Weeks
10g	USD 3,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Biapenem; CL 186,815; CL-186,815; CL186,815; L 627; L-627; L627; LJC 10,627; LJC-10,627; LJC10,627; RPX2003; RPX 2003; RPX-2003; Omegacin;

IUPAC/Chemical Name

(4R,5S,6S)-3-((6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium-6-yl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

InChi Key

MRMBZHPJVKCOMA-WAOAVRLKSA-N

InChi Code

InChI=1S/C15H18N4O4S/c1-7-11-10(8(2)20)14(21)19(11)12(15(22)23)13(7)24-9-3-17-5-16-6-18(17)4-9/h5-11,20H,3-4H2,1-2H3/t7-,8?,10-,11-/m1/s1

SMILES Code

O=C(C(N12)=C(SC(C3)CN4[N+]3=CN=C4)[C@H](C)[C@]2([H])[C@@H](C(O)C)C1=O)[O-]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO.

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Biapenem is a carbapenem antibacterial agent.

In vitro activity:

Biapenem/rifampicin activity was evaluated using three strains of M. tuberculosis : strain 115R (low-level rifampicin resistance); strain 124R (high-level rifampicin resistance); and the drug-susceptible H37Rv parent strain. In vitro , synergy was observed between biapenem and rifampicin against H37Rv and strain 115R. Reference: Biomed Environ Sci. 2019 Apr;32(4):235-241. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890701

In vivo activity:

In vivo , biapenem exhibited clear dose-dependent activity against H37Rv, with all biapenem doses as active or more active than rifampicin alone. Biapenem and rifampicin had synergistic bactericidal activity against H37Rv in the mouse model; no synergy was observed in mice infected with either of the rifampicin-resistant strains. Biapenem alone was active against all three strains. Reference: Biomed Environ Sci. 2019 Apr;32(4):235-241. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890701

	Solvent	mg/mL	mM
Solubility
	Water	7.5	21.40
	PBS (pH 7.2)	5.0	14.27

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 350.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Kaushik A, Ammerman NC, Tasneen R, Story-Roller E, Dooley KE, Dorman SE, Nuermberger EL, Lamichhane G. In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother. 2017 Aug 1;72(8):2320-2325. doi: 10.1093/jac/dkx152. PMID: 28575382; PMCID: PMC5890701. 2. Guo ZY, Zhao WJ, Zheng MQ, Liu S, Yan CX, Li P, Xu SF. Activities of Biapenem against Mycobacterium tuberculosis in Macrophages and Mice. Biomed Environ Sci. 2019 Apr;32(4):235-241. doi: 10.3967/bes2019.033. PMID: 31217059. 3. Kaushik A, Ammerman NC, Tasneen R, Story-Roller E, Dooley KE, Dorman SE, Nuermberger EL, Lamichhane G. In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother. 2017 Aug 1;72(8):2320-2325. doi: 10.1093/jac/dkx152. PMID: 28575382; PMCID: PMC5890701. 4. Guo ZY, Zhao WJ, Zheng MQ, Liu S, Yan CX, Li P, Xu SF. Activities of Biapenem against Mycobacterium tuberculosis in Macrophages and Mice. Biomed Environ Sci. 2019 Apr;32(4):235-241. doi: 10.3967/bes2019.033. PMID: 31217059

In vitro protocol:

In vivo protocol:

1: Nakagawa Y, Suzuki K, Hirose T, Chou T, Fujisawa S, Kida M, Usuki K, Ishida Y, Taniguchi S, Kouzai Y, Tomoyasu S, Miyazaki K, Higashihara M, Ando K, Aoki S, Arai A, Akiyama N, Hatake K, Okamoto S, Dan K, Ohyashiki K, Urabe A. Erratum to: Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study. J Infect Chemother. 2010 Dec 8. [Epub ahead of print] PubMed PMID: 21140280. 2: Jia B, Lu P, Huang W, Li C, Huang A, Zhou X, Zhang W, Wu G, Zhang G. A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections. Chemotherapy. 2010;56(4):285-90. Epub 2010 Aug 11. PubMed PMID: 20714145. 3: Nakagawa Y, Suzuki K, Hirose T, Chou T, Fujisawa S, Kida M, Usuki K, Ishida Y, Taniguchi S, Kouzai Y, Tomoyasu S, Miyazaki K, Higashihara M, Ando K, Aoki S, Arai A, Akiyama N, Hatake K, Okamoto S, Dan K, Ohyashiki K, Urabe A. Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study. J Infect Chemother. 2010 Jul 3. [Epub ahead of print] PubMed PMID: 20602137. 4: Kameda K, Ikawa K, Ikeda K, Morikawa N, Nakashima A, Ohge H, Sueda T. HPLC method for measuring meropenem and biapenem concentrations in human peritoneal fluid and bile: application to comparative pharmacokinetic investigations. J Chromatogr Sci. 2010 May-Jun;48(5):406-11. PubMed PMID: 20515537. 5: Thamlikitkul V, Trakulsomboon S. In vitro activity of biapenem against Burkholderia pseudomallei. Int J Antimicrob Agents. 2010 May;35(5):514. Epub 2010 Feb 25. PubMed PMID: 20188524. 6: Kikuchi E, Kikuchi J, Nasuhara Y, Oizumi S, Ishizaka A, Nishimura M. Comparison of the pharmacodynamics of biapenem in bronchial epithelial lining fluid in healthy volunteers given half-hour and three-hour intravenous infusions. Antimicrob Agents Chemother. 2009 Jul;53(7):2799-803. Epub 2009 Apr 20. PubMed PMID: 19380601; PubMed Central PMCID: PMC2704648. 7: Kameda K, Miki M, Ikawa K, Morikawa N, Kobayashi M. [Dosing regimen rationalization of biapenem in pediatric patients: use of Monte Carlo simulation]. Jpn J Antibiot. 2009 Feb;62(1):1-8. Japanese. PubMed PMID: 19378765. 8: Ikawa K, Morikawa N, Ikeda K, Katagiri M, Kiya K, Isobe N, Mizoue T, Kondo H, Takano M. Pharmacokinetics and pharmacodynamics of biapenem in human cerebrospinal fluid. Int J Antimicrob Agents. 2009 Aug;34(2):184-5. PubMed PMID: 19307107. 9: Xia M, Hang TJ, Zhang F, Li XM, Xu XY. The stability of biapenem and structural identification of impurities in aqueous solution. J Pharm Biomed Anal. 2009 May 1;49(4):937-44. Epub 2009 Feb 13. PubMed PMID: 19278804. 10: Suyama H, Ikawa K, Morikawa N, Ikeda K, Fujiue Y, Morikawa S, Kaneko K, Kuwabara M, Yamanoue T. Pharmacokinetics and pharmacodynamics of biapenem in critically ill patients under continuous venovenous hemodiafiltration. Jpn J Antibiot. 2008 Oct;61(5):303-13. PubMed PMID: 19260350.